Google, Microsoft May Pose Threats to Patient Privacy


By Maureen McKinney

April 22, 2008 | The entry of corporate behemoths like Google and Microsoft into the health information industry could have fundamental impacts on patient privacy, as well as on clinical research, according to an April 17 article in the New England Journal of Medicine.

The article, entitled, “Tectonic Shifts in the Health Information Economy,” differentiated personally controlled health records (PCHRs) from basic personal health records because PCHRs place primary control of data use and disclosure in the hands of patients. The authors cited the need for collaboration among PCHR providers, academic medical centers and the government in order to reach a consensus about appropriate methods of preserving data security and conducting research.

“Giving someone access to data that is institutionally controlled may have some benefits for the patient including insight into their own care, but with PCHRs, we go well beyond the walls of the institution,” explained Kenneth Mandl, associate professor at Children’s Hospital Boston, and co-author of the article. “Patients can engage with other institutions and entities, while the data flows into a repository that is exclusively controlled by the patient.”

One major concern with this dramatic increase in data liquidity, said Mandl, is that corporate entities entering the personal health record field are not held to the same standards as an academic research institution. Because companies like Google currently say they do not have to comply with the requirements and safeguards of the Health Insurance Portability and Accountability Act (HIPAA), there is no indication if they will adhere to research standards, he said.

“Under HIPAA, if one is to do research, they go before an institutional review board, which operates under the federal government and reviews protocols on how the data should be used,” Mandl said. “There are restrictions as far as aggregating patient data, benefits, risks, and notification. That’s a clear system of oversight, but with PCHRs, data from the repositories may be used for various kinds of research including drug approval and marketing.”

In addition, Mandl said, academic research centers may be at a disadvantage because not only do they have to comply with HIPAA protocols, they also might not have access to patient data pools as large as those of HealthVault and Google. If the largest and most complete databases reside on PCHR servers, it prompts questions about those companies’ research missions, the authors said.

In one example scenario provided in the article, a patient grants PCHR access to a clinical trial of a new medication, a medical social networking site, and an government-sponsored postmarketing surveillance program—none of which provide any informational control to medical centers.

“There is a reasonable argument that such control has been parochial and has created inefficiencies in fostering scientific discoveries and in delivering high-quality clinical care,” the authors said. “Nonetheless, if the pendulum swings the other way, and entire generation of clinical researchers in training will find themselves with second-class or no access to the best research resources.”

Patient privacy in PCHRs also remains uncertain and depends largely on how the hosting services of these companies approach the issue and inform their clients about the risks of certain types of disclosures, said Isaac Kohane, associate professor at Children’s Hospital Boston, director of the hospital’s informatics program, and co-author of the article.

Mandl and Kohane cited several critical steps that must be taken in order for PCHRs to be effective including the free exchange of patient data using agreed-upon standards, greater adoption of electronic health records, and new methods for protecting identity and security.

“Frankly, we don’t know what the optimal way is right now,” said Mandl. “We do think patients deserve guideposts, so we need to find the right mix that encourages discovery and, at the same time, protects the individual. That’s a conversation that PCHR service providers and medical centers need to be having.”

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

This Bio•IT World Briefing On “Next-Generation Sequencing,” underwritten by GenomeQuest, Inc.,
presents a selection of feature stories, interviews,commentaries, conference reports, and editorials on the emergence, opportunities, and challenges posed by high-throughput sequencing. Covered in this collection: the launch of new platforms from Applied Biosystems and Helicos; new applications of nextgen sequencing; the rise of personal genomics; and informatics solutions to vexing problem of managing the vast volumes of next-gen data. Download now



SGI's Meeting Today’s Computational Needs for Science
The quest to better understand disease mechanisms and find new treatments is driven by new laboratory technologies and ever-more sophisticated modeling and simulation efforts. As such, life sciences R&D investigations increasingly are relying on more powerful computing resources. The challenge is how to accommodate the broad mix of applications.

Addressing this issue, this paper produced by the Bio-IT World Custom Publishing Group discusses a new SGI Hybrid Computing Environment approach. It optimally uses shared memory systems, multi-processor clusters, and FPGAs to accelerate computational workflows. Download This Free Paper



SGI's Supercharging Proteomics Discovery
The deeper study of proteins and their interactions can reveal scientific information once considered nearly untouchable to scientists and researchers. Today, unprecedented advancements in computing power are enabling the creation of mounds of proteomic based data along with the accompanying bottlenecks data can create.

Rather than just “simplify the experiment” to fit the computational resources an alternative is now available with the SGI Proteomics Appliance. This complimentary white paper, produced by the Bio-IT World Custom Publishing Group, looks at ways to use the Proteomic Appliance to handle the most intensive proteomics computing tasks facing science today. Download This Free Paper



Life Science Webcasts & Podcasts

Waters

Streamlining the Chromatographic Method Validation Process

Waters® Empower™ 2 Method Validation Manager (MVM) is a business-critical, compliant-ready software that reduces time and costs required to perform chromatographic method validation by as much as 80%. Learn in this podcast how MVM streamlines the method validation process and allows the entire process to be efficiently performed within Empower 2, so fewer software applications need be deployed, validated, and maintained. Download Now


More Podcasts

Job Openings

Lilly Singapore Center for Drug Discovery (LSCDD) - Associate Director of Informatics
Lead and mentor a strong team for the Bioinformatics group at the Integrative Computational Sciences (ICS) department at LSCDD towards the development of novel algorithms, data analysis methods and software tools for drug discovery. Work closely with the Software Engineering group at ICS, and collaborate with the Discovery IT organization in Europe and USA. For additional information, or to apply visit: LSCDD

Lilly Singapore Center for Drug Discovery (LSCDD) - Senior Software Engineer
Join a strong team of software engineers in our Integrative Computational Sciences (ICS) at LSCDD. Collaborate with, and help develop integrated applications to process and visualize data from cutting-edge technologies used by scientists at Lilly Research Labs (LRL) and the Drug Discovery Research (DDR) teams. The Software Engineering team provides computational tools and tailored software solutions that enable the global effort of Tailored Therapeutics; ‘The Right Drug, at The Right Dose for The Right Patient at The Right Time'. For additional information, or to apply visit: LSCDD

Related Resources & Products

Disease-Related Biomarkers: Their Potential in Patient Screening, Prognosis, and Stratification
Disease-Related Biomarkers: Their Potential in Patient Screening, Prognosis, and Stratification
Patient Recruitment and Retention 2008
Genome-Based Biomarkers for Adverse Drug Effects, Patient enrichment and Prediction of Drug Response, and Their Incorporation Into Clinical Trial Design



For reprints and/or copyright permission, please contact RMS, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext 100 or via email to [email protected].